Effect of Vinca Alkaloids on the Expression Levels of microRNAs Targeting Apoptosis-related Genes in Breast Cancer Cell Lines

Mavrogiannis, Adamantios V.; Kokkinopoulou, Ioanna; Kontos, Christos K.; Sideris, Diamantis C.

doi:10.2174/1389201019666181112103204

Cited by 26 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, oncogene-miR-221 has also been reported to play a role in the mechanism of drug resistance in non-small cell lung cancer (10). Although miR-221-3p has been extensively investigated in BC (11)(12)(13)(14), the specific function of BC-secreted exosomal miR-221-3p in BC drug resistance still remains unclear. A recent study explored the role of miR-221 targeting phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) in cholangiocarcinoma cells (15).…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1

et al. 2020

View full text Add to dashboard Cite

Drug resistance in breast cancer (BC) cells continues to be a stern obstacle hindering BC treatment. Adriamycin (ADR) is a frequently employed chemotherapy agent used to treat BC. The exosomal transfer of microRNAs (miRNAs) has been reported to enhance the drug-resistance of BC cells. Herein, we first sought to elucidate the possible role of the exosomal transfer of miR-221-3p in the drug resistance of MCF-7 cells to ADR. Differentially expressed genes (DEGs) were initially screened through microarray analysis in BC drug resistance-related datasets. Next, the expression of miR-221-3p and phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) was quantified in ADR-resistant MCF-7 (MCF-7/ADR) and ADR-sensitive MCF-7 (MCF-7/S) cell lines, after which exosomes were separated and identified in each cell line. Target relationship between miR-221-3p and PIK3R1 was validated by a dual-luciferase reporter assay. Next, the expression of miR-221-3p and PIK3R1 was altered to clarify their effects on the resistance of MCF-7 cells to ADR in vitro and in vivo. PIK3R1 was identified as a BC drug resistance-related DEG, with the regulatory miR-221-3p subsequently obtained. Moreover, the MCF-7/ADR cells exhibited a low expression of PIK3R1 and a high expression of miR-221-3p. Notably, PIK3R1 was identified as a target gene of miR-221-3p. The overexpression of miR-221-3p in MCF-7/ADR cell-derived exosomes promoted ADR resistance in MCF-7/S cells via the PI3K/AKT signaling pathway. The in vitro results were reproducible in in vivo assays. Taken together, drug-resistant BC cell-derived exosomal miR-221-3p can promote the resistance of BC cells to ADR by targeting PIK3R1 via the PI3K/AKT signaling pathway in vitro and in vivo. These findings provide encouraging insights and provide perspectives for further investigation into the BC drug resistance mechanism.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Chemoresistance and new drug targets. The resistance of tumors to various anticancer drugs is an important factor that increases the invasiveness and metastasis of tumor cells (88,89), which depend on escaping apoptosis and increasing drug efflux (24,90). Dysregulated miR-222-3p expression may contribute to drug resistance by regulating gene expression (37), the cell cycle and apoptosis (26,37).…”

Section: Mir-222-3p As a Non-invasive Prognostic Biomarker In Cancermentioning

confidence: 99%

Emerging roles and mechanisms of microRNA‑222‑3p in human cancer (Review)

et al. 2021

View full text Add to dashboard Cite

MicroRNAs (miRNAs/miRs) are a class of small non-coding RNAs that maintain the precise balance of various physiological processes through regulating the function of target mRNAs. Dysregulation of miRNAs is closely associated with various types of human cancer. miR-222-3p is considered a canonical factor affecting the expression and signal transduction of multiple genes involved in tumor occurrence and progression. miR-222-3p in human biofluids, such as urine and plasma, may be a potential biomarker for the early diagnosis of tumors. In addition, miR-222-3p acts as a prognostic factor for the survival of patients with cancer. The present review first summarizes and discusses the role of miR-222-3p as a biomarker for diverse types of cancers, and then focuses on its essential roles in tumorigenesis, progression, metastasis and chemoresistance. Finally, the current understanding of the regulatory mechanisms of miR-222-3p at the molecular level are summarized. Overall, the current evidence highlights the crucial role of miR-222-3p in cancer diagnosis, prognosis and treatment.

show abstract

“…Aberrant DNA methylation of promoter regions is widely observed in human cancer and results in suppression of the expression of genes and miRNA (7,8). In our previous studies, it was demonstrated that genes silenced by DNA methylation serve important roles in the progression and chemosensitivity of endometrial cancer (23)(24)(25)(26).…”

Section: Discussionmentioning

confidence: 99%

“…These molecules can regulate the expression of hundreds of target genes, and serve important regulatory roles in fundamental biological processes, including cell proliferation, differentiation and apoptosis via negative regulation of gene expression (3)(4)(5). Consistent with their roles in these processes, a number of studies have identified widespread alteration of miRNA expression in cancer (6)(7)(8). miRNAs may function as tumor suppressors or oncogenes, and dysregulation of miRNA expression is associated with tumorigenesis, cancer progression and metastasis.…”

Section: Introductionmentioning

confidence: 98%

MicroRNA‑34b expression enhances chemosensitivity of endometrial cancer cells to paclitaxel

2020

View full text Add to dashboard Cite

Aberrant DNA methylation is widely observed in various types of cancer, and expression of microRNAs (miRNAs/miRs) is suppressed by DNA methylation. The present study explored tumor suppressor miRNAs downregulated by DNA methylation in endometrial cancer cells, as the basis of a novel therapeutic approach for endometrial cancer. Among 821 candidate miRNAs, miR-34b was identified as an upregulated miRNA after demethylation treatment in all four endometrial cancer cell lines (HEC-108, SNG-II, Ishikawa and HHUA) examined. miR-34b expression with or without demethylation treatment in cancer cells was confirmed by TaqMan quantitative PCR. MYC and MET , the predicted target genes of miR-34b, were downregulated at both the RNA and protein levels following miR-34b overexpression. Following miR-34b treatment, inhibition of cell growth and invasion, and cell cycle arrest were observed in HEC-108 cells. Sensitivity to paclitaxel was increased in cancer cells with miR-34b overexpression, compared with untreated cancer cells, but this difference was not identified for cisplatin or doxorubicin. In vivo , combination treatment with miR-34b and paclitaxel markedly reduced tumor growth compared with treatment with negative control miRNA and paclitaxel. These data suggest that miR-34b enhances paclitaxel sensitivity in endometrial cancer cells, and that miR-34b and MET are key targets for treatment of endometrial cancer. The present results may contribute to the development of combination treatment with a demethylation agent, miR-34b mimic or MET inhibitor and an anticancer drug.

show abstract

Effect of Vinca Alkaloids on the Expression Levels of microRNAs Targeting Apoptosis-related Genes in Breast Cancer Cell Lines

Cited by 26 publications

References 0 publications

RETRACTED: Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1

RETRACTED: Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1

Emerging roles and mechanisms of microRNA‑222‑3p in human cancer (Review)

MicroRNA‑34b expression enhances chemosensitivity of endometrial cancer cells to paclitaxel

Contact Info

Product

Resources

About